Estimating Sensitivity and Specificity from a Phase 2 Biomarker Study that Allows for Early Termination by Pepe, Margaret S, PhD
UW Biostatistics Working Paper Series
12-12-2007
Estimating Sensitivity and Specificity from a Phase
2 Biomarker Study that Allows for Early
Termination
Margaret S. Pepe PhD
Fred Hutchinson Cancer Research Center, nnoble@fhcrc.org
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors
Suggested Citation
Pepe, Margaret S. PhD, "Estimating Sensitivity and Specificity from a Phase 2 Biomarker Study that Allows for Early Termination"
(December 2007). UW Biostatistics Working Paper Series. Working Paper 321.
http://biostats.bepress.com/uwbiostat/paper321
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Study that Allows for Early Termination
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1 Fred Hutchinson Cancer Research Center
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SUMMARY
Development of a disease screening biomarker involves several phases. In phase 2 its sensitivity and
specificity is compared with established thresholds for minimally acceptable performance. Since we
anticipate that most candidate markers will not prove to be useful and availability of specimens and
funding is limited, early termination of a study is appropriate if accumulating data indicate that the
marker is inadequate. Yet, for markers that complete phase 2, we seek estimates of sensitivity and
specificity to proceed with the design of subsequent phase 3 studies.
We suggest early stopping criteria and estimation procedures that adjust for bias caused by the early
termination option. A novel aspect of our approach is to focus on properties of estimates conditional
on reaching full study enrollment. We propose the conditional-UMVUE and contrast it with other
estimates, including na¨ıve estimators, the well studied unconditional-UMVUE and the mean and
median Whitehead adjusted estimators. The conditional-UMVUE appears to be a very good choice.
Copyright c© 2008 John Wiley & Sons, Ltd.
1. Introduction
The Early Detection Research Network (EDRN) seeks to develop biomarkers for cancer
screening, diagnosis, prognosis and risk prediction. Marker development is a process, a sequence
of studies. A 5-phase paradigm for this process has been adopted for the development of
screening markers [1]. Brieﬂy, phase 1 concerns marker discovery, phase 2 is retrospective
marker validation in specimens from cases concurrent with clinical disease and controls
without, phase 3 is retrospective marker validation in specimens taken prior to clinical disease,
phase 4 is a prospective population study of test performance and phase 5 is ideally a
randomized trial comparing mortality in the presence and absence of screening. Most of the
studies conducted by EDRN are phase 1 and 2. Here we consider the design of a phase 2 study.
Stored blood or urine specimens are typically used in a phase 2 study. The marker is
measured in specimens from a set of cases with clinical disease and from a set of appropriate
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controls. Considerable eﬀort has been expended to establish high quality specimen repositories
for breast, lung and prostate cancer within the EDRN. Other groups have similarly built
specimen banks for biomarker evaluation. It is important to use these resources judiciously
and eﬃciently.
There is great enthusiasm in the scientiﬁc and business communities about the potential for
technology to measure biomarkers [2]. Biomarker discovery studies abound and we anticipate
that a large number of candidate biomarkers will be put forward for validation. However, the
false discovery rate from phase 1 is likely to be high. That is, we expect that the majority
of markers studied in phase 2 will not have adequate performance for proceeding to further
development. This, along with concerns about conserving specimen resources and keeping
study costs reasonable motivate a group sequential approach to phase 2 study design. In
particular, designs that allow early termination when accumulating evidence suggests poor
marker performance, are very attractive.
In this paper we consider dichotomous markers, with values denoted by Y = 1 for a positive
result and Y = 0 for a negative result. Let D be the disease indicator, D = 1 for cases and
D = 0 for controls. Marker performance is quantiﬁed by the sensitivity, S = P [Y = 1|D = 1],
and the false positive rate (or 1−speciﬁcity), F = P [Y = 1|D = 0]. Higher sensitivities and
lower false positive rates indicate better performance.
When a phase 2 study terminates early, the marker is not considered for further development.
In contrast when a study completes its full enrollment, estimates of (S, F ) will be calculated
to determine if and how marker development should proceed further. Our particular interest
is in estimating (S, F ) with data from completed phase 2 studies, i.e., from studies that do not
terminate early.
Group sequential methods have received scant attention in the diagnostic testing literature.
Mazumdar and Mazumdar and Liu [3, 4] consider methods for prospective comparative studies
with early termination possible for either positive or negative conclusions. The context is geared
towards phase 4 studies, not for phase 2 validation studies. There is no existing group sequential
methodology for phase 2 biomarker studies.
Phase 2 treatment trials have statistical elements in common with our paradigm for phase 2
biomarker studies. In the prototype phase 2 treatment trial, subjects are classiﬁed as responders
or not, the parameter of interest is the binomial response probability, and early termination
occurs if the observed response rate is low. In our setting there are two binomial probabilities,
S in cases and F in controls, and a study terminates early if either is clearly unsatisfactory.
For simplicity we will ﬁrst describe methodology when only one binomial probability is
of interest and later address extensions to simultaneous consideration of two independent
binomial proportions. We note that our methods are equally relevant to phase 2 treatment
trials, although our motivation derived from phase 2 biomarker study design.
Substantial methodology has been developed for estimation following the group sequential
design of a phase 2 therapeutic study. A key distinction between previous methods and what
we propose here is that we are concerned with estimation only when a study reaches its
planned full sample size. We consider properties of estimators conditional on study completion
whereas previous methods provide an estimator at the terminating stage, early or not, and their
unconditional properties are evaluated. The marginalized mean and variance of estimators are
evaluated from all studies, those that terminate early and those that do not. We believe that
estimation is less important if a study terminates early since the biomarker is clearly inadequate
when that occurs and estimates for planning phase 3 are not needed. Moreover, conﬁdence
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intervals would be too wide with the smaller sample sizes for estimates to be meaningful when
a study terminates early. Therefore estimation conditional on reaching the full sample size is
our focus. We return to this important point in Section 4.
In Sections 2 through 6 we discuss estimation of a single binomial probability. The two-stage
group sequential design is described in Section 2 and estimators are deﬁned. Simulation studies
described in Section 3 are used to compare them. We contrast unconditional estimation with
conditional estimation in Section 4 and argue that our conditional estimators may be useful
even if unconditional estimation is required. Inference is the topic of Section 5 where methods
to construct conﬁdence intervals with the bootstrap are described along with associated
hypothesis testing procedures. Some applications illustrate our approach in Section 6. In
Section 7 we return to the context of studying performance of diagnostic tests, illustrating
in detail our procedures when two binomial parameters, (S, F ), are simultaneously under
consideration. Some closing remarks and directions for further work are provided in Section 8.
2. Design and Estimation
2.1. Design
We consider a single binomial probability, S = P [Y = 1], which could denote the response rate
in a phase 2 therapeutic study, though we use terminology from diagnostic studies here and
let S be the sensitivity, i.e., the rate of positive biomarker responses in cases. Suppose that
sensitivities below γ0 are undesirable while values at or above γ1 are desirable. In particular
in phase 2 we will need to show that S > γ0, the maximal undesirable sensitivity, in order
to proceed with phase 3 development. On the other hand, γ1 is minimally desirable in the
following sense: if S > γ1 we certainly want to proceed with development while for S(γ0 , γ1),
the equivocal region of sensitivities, there is little enthusiasm. In terms of hypotheses upon
which to base study design, we write
H0 : S ≤ γ0 versus H1 : S = γ1.
High power is sought only if S ≥ γ1. As an example, for detection of ovarian cancer sensitivities
below γ0 = 0.6 would be undesirable since existing markers reach at least this level of detection
while we seek markers with sensitivities of at least γ1 = 0.8, since this would be a substantial
improvement and worth investing resources for further research.
A single stage study will enroll n cases with disease and reject H0 if the lower two-sided
(1−α) conﬁdence limit for S exceeds γ0 . For the purposes of study monitoring after m samples
are evaluated, we propose to construct a two-sided (1−δ)×100% conﬁdence interval, and if the
upper limit is less than γ1, the study terminates. That is, if there is strong evidence that the
sensitivity is below the minimally desirable level, the study will not continue to completion.
Otherwise, the study continues to evaluate the remaining n−m samples. This stopping rule
is reasonable and easy to explain to investigators. Moreover, under H1 there is only a small
chance, δ/2, of stopping early, suggesting that it will maintain statistical power relative to a
single stage study.
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2.2. Estimation at Study Completion
We now consider how to estimate the sensitivity, S, at the end of a completed phase 2 study.
The data are denoted by {Yi, i = 1, . . . n} with the index i indicating the order in which
samples are evaluated. One option is to calculate the na¨ıve estimator that ignores the early
stopping procedure
Ŝ(all) =
n∑
i=1
Yi/n.
However this is likely to be biased upward since it is contingent upon an adequately high
response rate amongst the ﬁrst m samples to result in completing the study. An unbiased
estimator that is unaﬀected by the early stopping option uses only the second stage samples,
Ŝ(stage2) =
n∑
i=m+1
Yi/(n−m).
Because of the relatively small sample size this estimator is likely to suﬀer from imprecision.
We now propose an unbiased estimator that incorporates data from both stages. Having
used Ŝ to denote simple proportions we write this more complicated estimator as
Û = E(Ŝ(stage2)|Ŝ(all), C = 1)
where C = 1 indicates that the criterion for continuation past the ﬁrst stage was passed.
Result 1
Conditional on C = 1, Ŝ(all) is a complete and suﬃcient statistic for the distribution of
Ŝ(stage2).
Proof
For suﬃciency we need to show that the conditional distribution of Ŝ(stage2) given
Ŝ(all) and C = 1 does not depend on the parameter S. But conditional on Ŝ(all), the
distribution of Ŝ(stage2) is hypergeometric (n, n − m, Ŝ(all)). Moreover, since Ŝ(stage1) =
m−1{nŜ(all) − (n − m)Ŝ(stage2)}, C can be determined from Ŝ(all) and Ŝ(stage2). The
distribution of Ŝ(stage2) conditioning on C = 1 in addition to Ŝ(all) can be derived from the
distribution of Ŝ(stage2) conditioning on Ŝ(all):
P (Ŝ(stage2)|Ŝ(all), C = 1) = I(C = 1)P (Ŝ(stage2)|Ŝ(all))
P (C = 1|Ŝ(all)) .
Therefore, since P (Ŝ(stage2)|Ŝ(all)) does not depend on S, neither does P (Ŝ(stage2)|Ŝ(all), C =
1). The proof of completeness follows from detailed tedious arguments given in Appendix A
of Jung and Kim [5].
Corollary
Û is the unique minimum variance unbiased estimator of S among all estimators that are
unbiased conditional on C = 1.
Proof
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This follows from the fact that Ŝ(stage2) is independent of C and hence conditionally
unbiased
E(Ŝ(stage2)|C = 1) = E(Ŝ(stage2)) = S
and the Rao-Blackwell theorem [6].
Two other estimators are inspired by Whitehead [?]. They adjust Ŝ(all) for bias caused by
the early termination option. The median adjusted estimator is
Ŵmed = γ : Pγ(Ŝ
∗(all) > Ŝ(all)|C∗ = 1) = 0.5, (1)
where the ∗ superscript denotes random variables generated from our study design using γ
as the binomial response probability, γ = Pγ(Y = 1). Intuitively, Ŵmed is the response
probability for which the observed na¨ıve proportion is the median na¨ıve proportion in studies
that continue to completion. A mean adjusted estimator is similarly deﬁned
Ŵmean = γ : Eγ(Ŝ∗(all)|C∗ = 1) = Ŝ(all), (2)
2.3. Calculations
We calculate Û , Ŵmed and Ŵmean numerically using simulations. For Û , we noted earlier
that the conditional distribution of Ŝ(stage2) given Ŝ(all) is hypergeometric. Therefore, in
each of K simulations we sample m cases at random from the n available to simulate the ﬁrst
stage data, and the remaining n −m simulate the second stage data. Accordingly, in the kth
simulation, values of Ŝk(stage2), Ŝk(stage1) and Ck are calculated. Averaging Ŝk(stage2)
across simulations where Ck = 1 yields Û . Exact calculations using the hypergeometric
distribution are also possible.
More extensive computations are required for calculating Ŵmed and Ŵmean, because they
involve searching for γ to satisfy (1) and (2), respectively. For each value of γ considered
we simulate two stage studies with binomial probability equal to γ and select Ŝk(all) for
studies that satisfy Ck = 1. We calculate Pγ(Ŝ∗(all) > Ŝ(all)|C∗ = 1) as the proportion of
Ŝk(all) exceeding the observed Ŝ(all), and Eγ(Ŝ∗(all)|C∗ = 1) is calculated as the mean
of Ŝk(all). Ŵmed is the γ for which Pγ(Ŝ
∗(all) > Ŝ(all)|C∗ = 1) is closest to 0.5 and
Ŵmean is the γ for which Eγ(Ŝ∗(all)|C∗ = 1) is closest to Ŝ(all). In our applications we
used K = 5000 simulations to calculate Û . Also for each γ, Pγ(Ŝ∗(all) > Ŝ(all)|C∗ = 1)
and Eγ(Ŝ∗(all)|C∗ = 1) were calculated with K = 5000 simulations, we selected Ŵmed=γ if
Pγ(Ŝ∗(all) > Ŝ(all)|C∗ = 1) was within 0.005 of 0.5, and Ŵmean=γ if Eγ(Ŝ∗(all)|C∗ = 1)
was within 0.005 of Ŝ(all).
3. Performance of Estimators
3.1. Initial Assessment
A single stage study to test H0 : S ≤ γ0 = 0.6 with 90% power at H1 : S = γ1 = 0.8 and
allowing type 1 error rate α = 0.05 requires 42 cases according to asymptotic theory formulas
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[9]. We simulated 1000 studies with n = 40 allowing for early termination after responses from
m = 20 are observed if the upper two-sided 95% conﬁdence limit for S [10] does not exceed
γ1 = 0.8. Results in Table 1 show estimates calculated from studies that complete enrollment
of all 40 cases. If the true sensitivity is low, it is likely that the study will terminate early. For
example, when S = 0.6, 59.2% of studies stop early while 40.8% continue to full enrollment of
n = 40. Thus the means and standard deviations in the corresponding row of Table 1 relate
to 40.8% × 1000 = 408 studies. Consider ﬁrst the na¨ıve estimator, Ŝ(all), that ignores the
early stopping option. The anticipated upward bias is evident, and most pronounced when S
is small. For example, when S = 0.55 the mean is 0.62, a substantial bias. When S is at the
null hypothesis value, S = .60, the bias leads to a type 1 error rate that is twice the nominal
value. The other na¨ıve estimator using only second stage data, Ŝ(stage2) is unbiased. However,
its precision is low, a problem that is evident when the probability of early stopping is very
small (i.e., S is large). Indeed when no studies terminate early (e.g., S = 0.85), we note that
var(Ŝ(stage2)) = n
n−mvar(Ŝ(all)) in general.
The conditional UMVUE, Û , appears to maintain the best properties of both na¨ıve
estimators. Like Ŝ(stage2), it is unbiased across all values of S. In addition, when early stopping
is unlikely, its precision is comparable with Ŝ(all). These results are encouraging.
The performances of the mean and median adjusted estimators are comparable with that
of Û . They substantially adjust for bias when S is low and are relatively precise when S is
large. Despite their good performance we will not study them further here for the following
reasons: (i) there is no theory to support them, unlike Û , which is theoretically unbiased. A
close look at Table 1 indicates some residual bias in Ŵmed; (ii) Their computation is more
diﬃcult than that for Û ; and (iii) Our preliminary simulation studies in Table 1 indicate no
particular improvement in their performances over that of Û .
3.2. Additional Scenarios
Table 2 shows additional simulation results for studies with larger sample sizes. The top panel
is motivated by the context of ovarian cancer screening where a very high speciﬁcity is desired.
False positive screening tests result in subjects undergoing laproscopic surgery, so the rate
must be kept very small. Speciﬁcity values at or above 0.98 are desired while values below 0.95
would be considered unacceptable. A single stage study would require n = 230 specimens from
non-diseased subjects, and we consider early termination after evaluating half that number,
m = 115. The bottom panel shows a setting similar to Table 1, but with γ1 = 0.70 rather than
γ1 = 0.80. The results corroborate those in Table 1.
We also investigated choices of m other than n/2 (Table 3). Since the criterion for early
stopping is based on the upper conﬁdence limit for S not exceeding γ1, the probability of
early stopping for S < γ1 is larger when more data is available at stage 1. On the other hand
the bias in the na¨ıve estimator Ŝ(all) for studies that complete is larger with larger value
of m. For example, with m/n = 27/40, if S = 0.55, 84% of studies terminate early and the
expectation of Ŝ(all) is 0.653. In contrast with m = 13/40, 59% of studies terminate early and
the expectation of Ŝ(all) is 0.592.
The conditional UMVUE, Û , is by deﬁnition conditionally unbiased, regardless of m, as is
borne out again by Table 3. Its variance, however, is larger with larger values of m, a point
we return to in section 6.
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4. Unconditional Estimation
Estimation following group sequential designs for phase 2 therapeutic trials has been studied
at least since 1958 [11]. We refer to Jennison and Turnbull [12] and Emerson and Fleming [13]
as key papers. The UMVUE for binary response data was studied recently by Jung and Kim
[5], although related results for the mean of a normal distribution have long been available [?].
For a two stage study with binary response, the UMVUE is easy to calculate and is likely the
popular choice so we consider it here.
The literature on group sequential designs considers that estimation occurs at the end of
the study, i.e., at stage 1 if the study terminates there or at stage 2 if it continues. The
unconditional UMVUE is deﬁned as
U˜ = E(Ŝ(stage1)|Ŝ, stage)
where stage denotes the stopping stage and Ŝ denotes the response rate calculated with all
data collected in the study by the stopping stage. Thus,
U˜ = Ŝ(stage1) if C = 0
U˜ = E(Ŝ(stage1)|Ŝ(all), C = 1) if C = 1.
Averaging over all studies, including those that terminate at stage 1, U˜ is unbiased because
Ŝ(stage1) is unbiased. However, if interest is in estimation only for studies that complete both
stages, then U˜ is biased upward, i.e., E(U˜ |C = 1) > S. Intuitively this follows from the fact
that since U˜ is marginally unbiased
S = E(U˜) = E(U˜ |C = 0)P (C = 0) +E(U˜ |C = 1)P (C = 1)
and E(U˜ |C = 0) = E(Ŝ(stage1)|C = 0), is the mean response in stage 1 restricted to
studies that terminate early for lack of response, which, by deﬁnition, is biased low. Therefore
E(U˜ |C = 1) is biased high. For the scenarios considered in Tables 1 and 2 we calculated the
conditional mean and sd of U˜ , shown in Table 4.
The estimates calculated from studies that complete stage 2 have substantial bias. In these
settings the bias is at least as large as that of the na¨ıve uncorrected estimator Ŝ(all). In
conclusion, if one is primarily interested in estimates of the response rate for studies that
complete evaluation of all n samples, we suggest using the conditional UMVUE, Û , over the
traditional unconditional UMVUE, U˜ .
We focus on estimation in studies that do not terminate early because our purpose is to
determine if and how to design the next study. In particular, they will be used in sample size
calculations. If a study terminates early due to lack of response, we conclude that S < γ1 and
the biomarker is considered inadequate for further development. The estimate and its sampling
variability are usually not of great interest.
Nevertheless, we believe that there may also be a role for the conditional UMVUE in
the traditional group sequential design settings where estimation at the terminating stage
is required, be it early or not. Deﬁne
U∗ = Ŝ(stage1) if C = 0
U∗ = Û if C = 1
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The estimator U∗ is equal to the traditional UMVUE if the study stops early and equal to
the conditional UMVUE if the study completes. It is unbiased conditional on completing both
stages, but is not marginally unbiased. Observe that
E(U˜ − S)2 − E(U∗ − S)2
= P (C = 1){E(U˜ − S)2 |C = 1)− E((Û − S)2|C = 1)}
= P (C = 1){var(U˜ |C = 1) + bias2(U˜ |C = 1)− var(Û |C = 1))}.
From Tables 1 and 4 we see that when S is low the bias in U˜ dominates and U∗ has smaller
(unconditional) mean squared error than U˜ . However, when the response rate is high there is
little bias in any of the estimates, including U˜ . In these cases the small conditional variance
of U˜ is attractive. In summary in terms of mean squared error, U˜ performs better than U∗
when the response rate is high but worse than U∗ when the response rate is low. In phase 2
biomarker development studies we anticipate that low response rates will be more common.
Hence we recommend Û and U∗ for conditional and unconditional estimation, respectively.
5. Inference with the Conditional UMVUE
5.1. Confidence Intervals
We seek not only an estimate of S at the end of a completed study, but a conﬁdence interval as
well. For this we propose two resampling methods. Note that simple bootstrapping, resampling
at random from {Yi, i = 1, . . . , n} is not valid under a group sequential design. The responses
in the observed data are biased due to having passed the early stopping criterion.
In the ﬁrst resampling approach we use the estimated population response rate, Û , to
simulate b = 1, . . . , B group sequential studies with our design. Selecting those for which
the continuation criterion is satisﬁed, Cb = 1, and calculating the corresponding statistics, Û b,
we use their empirical distribution as an estimate of the sampling distribution of Û , conditional
on C = 1. The α/2 and {1 − α/2} empirical quantiles are used as conﬁdence limits. We call
this approach the parametric bootstrap because data are simulated with response probability
Û , though we note that no parametric assumptions are made.
We call the second approach the nonparametric bootstrap. Here in the bth resampling,
we resample n responses with replacement from the n observed, and calculate Û b =
E(Ŝb(stage2)|Ŝb(all), C = 1). Again, quantiles of the distribution of Û b are used as conﬁdence
limits.
Table 5 shows coverage of conﬁdence intervals under the scenarios and design of Table
1 (n = 40, m = 20) and Table 2 (n = 220, m = 110). Due to the extensive computation
involved, we used K = 500 (rather than K = 5000) in calculating Û . We see that coverage is
reasonably close to the nominal 95% level for both bootstrap methods, but somewhat lower for
the parametric bootstrap than for the nonparametric bootstrap. Correspondingly, the standard
deviation tends to be slightly underestimated with the parametric methods but overestimated
with the nonparametric bootstrap.
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5.2. Power
We can use the conﬁdence interval to formally test H0 : S ≤ γ0. Recall that only values of
S at or above γ1 are considered desirable so we study power for S ≥ γ1. Compared to a
ﬁxed sample size study of n samples, power is reduced by the group sequential design for two
reasons. First, by allowing studies to stop at stage 1, power is lost if some fraction of those
would have proceeded to yield a positive conclusion had they not been terminated. Second,
power is lost if the width of the conﬁdence interval for S is wider when it is based on an
adjusted estimator than when it is based on the na¨ıve estimator.
The stopping criterion used plays a large role in regards to the ﬁrst power loss mechanism
(although the discussion so far in this paper does not rely on it). Our proposed criterion is to
stop after evaluating m subjects if the upper two-sided (1 − δ) conﬁdence limit lies below γ1 .
Therefore the associated power loss at S ≥ γ1 is no more than δ/2. It is likely to be less than
delta/2 even when S = γ1 because some of those terminated studies would presumably be in
the fraction of studies deemed to be negative even if enrollment continued to n samples.
Table 6 displays the power of the standard analysis based on Ŝ(all) in a ﬁxed sample size
design. That is, the power if all studies continued to n = 40 regardless of interim results. Also
shown are the powers associated with designs that allow early stopping and use conﬁdence
intervals based on Û at the end of stage 2 for testing H0 : S ≤ γ0. We see that two-stage
studies using the parametric bootstrap conﬁdence interval have power comparable with the
ﬁxed sample size power. That is, their beneﬁt, which is to terminate early those studies in
which markers have poor performance, is gained without substantial loss in their capacity to
identify good markers as such. The nonparametric bootstrap conﬁdence interval seems to not
achieve the same power, due presumably to their over conservative nature.
Our focus here is on power achieved when S ≥ γ1. We deﬁned γ1 as the minimum desirable
value of S meaning that values of S less than γ1 are not desirable. We therefore do not seek high
power for S in the range (γ0 , γ1). The two-stage design in fact ensures that power in this range
is reduced relative to a single stage study and we view this as a good attribute. Nevertheless,
it underscores that the choice of γ1 should be made judiciously and must be the minimum
desirable value. Similarly the choice of γ0 is crucial, γ0 is the maximal unacceptable values.
Values in the equivocal range (γ0, γ1) may be reluctantly acceptable but are not desirable.
Specifying (γ0, γ1) is often a diﬃcult challenge in practice.
6. Illustrations
To ﬁx ideas we now provide in Table 7 a few simple illustrations using simulated data. For each
we use the design of Table 1, i.e., n = 40, m = 20, γ0 = 0.6, γ1 = 0.8. In the ﬁrst illustration, at
the interim analysis only 5 of 20 samples have a positive response. The 95% conﬁdence interval
for S is (0.11,0.47). Since the upper limit is below γ1 = 0.80 the study terminates early.
In the second illustration, the response rate at the interim analysis is much higher, with 18
of 20 responses positive and 95% conﬁdence interval for S, (0.70,0.97). The study continues
to accrue responses from 20 more subjects, of which 17 responses are positive, yielding
Ŝ(all) = 35/40 = 0.88. The estimates that adjust for the early stopping option Û , Ŵmed,
and Ŵmean, are all equal to 0.88. We calculate 95% conﬁdence intervals for S based on Û as
(0.75,0.98) with the nonparametric bootstrap and (0.77,0.97) with the parametric bootstrap.
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In either case we conclude that the response rate exceeds the unacceptable level of 0.60. In
fact it appears to be within the desirable range and deliberations about the next phase of
biomarker development ensue.
Six further illustrations are shown in Table 7. Two, studies 3 and 8, terminate early. Two,
studies 4 and 5, continue to completion but do not yield positive conclusions about marker
performance. Study 6 is inconclusive. Unfortunately when the design stipulates only 90%
power, even with a ﬁxed sample size design inconclusive studies can occur. Study 7 indicates a
100% response rate (CI=(0.84,1.00)) in the initial stage. One might be tempted to terminate
at that point. However a more prudent approach is to collect additional data, and indeed the
second stage data tempers enthusiasm somewhat, providing adjusted estimates of 0.85 for the
response rate.
The results in Table 7 suggest relationships between Û , Ŝ(all) and Ŝ(stage2). In
particular when Ŝ(all) is large, we ﬁnd that Û ≈ Ŝ(all). This is reasonable since Û =
E(Ŝ(stage2)|Ŝ(all), C = 1), and when Ŝ(all) is large it follows that C = 1 with high
probability so that Û ≈ E(Ŝ(stage2)|Ŝ(all)) = Ŝ(all). On the other hand, when Ŝ(all) is
small, Û ≈ Ŝ(stage2). This makes sense because a small value of Ŝ(all) together with the
knowledge that the continuation criterion was passed indicates that Ŝ(stage1) was close to
the critical value for continuation. This in turn informs about Ŝ(stage2), which is equal to
(n −m)−1{nŜ(all) −mŜ(stage1)}.
These observations also have implications for the performance of Û relative to Ŝ(all) and
Ŝ(stage2) in general. When the true response rate is small, Û behaves similarly to Ŝ(stage2),
while Û behaves more like Ŝ(all) when the response rate is high. The conditional standard
deviations reported in Tables 1 and 2 bear this out. In addition, we see in Table 3 that diﬀering
values of m have little impact on the conditional performance of Û when S is large, but greater
impact when S is small. In the former case, Û is similar to Ŝ(all), which is unaﬀected by m.
In the latter case, Û is similar to Ŝ(stage2), which is more variable when the second stage
sample size n−m is small.
7. Simultaneous Inference for Sensitivity and Speciﬁcity
We now return to the context of evaluating a diagnostic or screening marker where
considerations of both sensitivity (S) and speciﬁcity (1 − F ) must be made simultaneously.
Let γ0 and η0 denote maximal unacceptable values of sensitivity and speciﬁcity, respectively,
while γ1 and η1 denote minimum desirable values. The design and analysis of a ﬁxed sample
size study are described in detail in Pepe, pages 218–220 [9].
Brieﬂy, using subscripts D and D¯ to denote cases and controls, a ﬁxed sample size study
enrolls nD cases and nD¯ controls. A joint conﬁdence (1 − α) rectangle for (S, 1 − F ) is
calculated as the Cartesian product of (1 − α∗) conﬁdence intervals for S and 1 − F where
(1 − α∗) = (1 − α) 12 . A positive conclusion is drawn about marker performance if the lower
limit for S exceeds γ0 and the lower limit for 1 − F exceeds η0. The sample sizes are chosen
so that when S = γ1 and 1 − F = η1 the probability is high, 1 − β, that both lower
conﬁdence limits exceed the thresholds γ0 and η0. To illustrate, with (γ0, γ1) = (0.6, 0.8) and
(η0, η1) = (0.95, 0.98), values appropriate for an ovarian cancer screening marker, the sample
size formulae (Pepe equations (8.2) and (8.3)) [9] yield nD = 78 and nD¯ = 572 to achieve size
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α = 0.05 and power 1− β = 0.90.
The study could be designed to terminate after half the cases and half the controls are
evaluated if the joint conﬁdence rectangle does not contain both minimally desirable values
for sensitivity and speciﬁcity (γ1 , η1). Otherwise the study continues to complete enrollment
at which time the conditional UMVUE estimates of S and 1−F are calculated. Corresponding
(1−α∗) level conﬁdence intervals yield a joint (1−α) conﬁdence rectangle. A positive conclusion
about marker performance ensues if the (1−α∗) conﬁdence intervals for S and 1−F exclude
γ0 and η0 respectively. Table 8 shows the results of some simulation studies.
We see that the study is likely to stop early if the true sensitivity or the true speciﬁcity is
low but likely to continue if both are at the minimally desirable value. Coverage for the 95%
parametric bootstrap conﬁdence rectangle was slightly lower than the nominal rate, although,
four of the ﬁve scenarios achieved at least 93% coverage. We observe that the study has very
low rejection rate when S < γ0 or 1 − F < η0, as desired. When S ≥ γ1 and 1 − F ≥ η1, we
desire high power. We observe that the 81% unconditional power when S = γ1 and 1−F = η1
represents a 9% decrease from the ﬁxed sample size power.
There are many variations on study design that could be explored. Our choice of interim
analysis when both mD = nD/2 cases and mD¯ = nD¯/2 controls are evaluated is arbitrary.
One need not enroll cases and controls at the same relative rates. In fact one option would be
to enroll all mD¯ controls ﬁrst before using samples from cases. If the study terminates early
because of poor speciﬁcity, precious samples from cases are saved. Yet inference is the same.
In practice however, one may want to mix up the order of cases and controls somewhat in
order to expose testers to heterogeneous samples and to aid with blinding. In a similar vein,
for S and F we have chosen equal adjusted signiﬁcance levels α∗ for construction of their joint
conﬁdence rectangle. Unequal values can be employed. Letting α∗D and α
∗¯
D
denote adjusted
values for S and F , respectively, the requirement for joint 1− α coverage is that
(1− α∗D)(1− α∗¯D) = 1− α.
However, arguments leading to particular choices of (α∗¯
d
, α∗D) that are unequal have not been
developed yet.
8. Conclusions and Remarks
We have proposed the conditional UMVUE, Û , for estimation at the end of a phase 2 group
sequential study that does not terminate early. It is appropriate when unbiased estimation is
required from studies that reach full enrollment. In our experience with phase 2 biomarker
studies, calculation of estimates is of less concern in studies that terminate early, where the
conclusion is simply that the biomarker is inadequate for further development and suﬃcient
data for precise estimation is not available in any case. Hence we focused on estimators with
good properties conditional on full enrollment. These considerations seem equally relevant
for phase 2 group sequential therapeutic studies and we suggest Û for application in that
context too. We noted that the standard unconditional UMVUE, Û , can show considerable
conditional bias. The naive unadjusted estimator is also conditionally biased, although in terms
of mean squared error and coverage of conﬁdence intervals it performed reasonably well in most
scenarios we considered.
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Conditional inference has been discussed from a decision theoretic point of view [16] and
was recently applied to group sequential designs [17]. In particular, Strickland and Casella
considered the conditional conﬁdence interval, (γL, γU ), where limits are deﬁned in a similar
vein to Whitehead’s median adjusted estimator but using target probabilities of α/2 and
1−α/2 instead of 0.5 in equation (1). For normally distributed data they proved an optimally
result for these intervals. This suggests that they be examined for binary data and compared
to the conﬁdence intervals based on Û that were proposed here. They also noted for normally
distributed data that the conditional performance of unconditional conﬁdence intervals can be
very poor.
The design of a group sequential study requires choosing values for the conﬁdence level at
the interim analysis, 1−δ, and for the stage 1 sampling fraction, m/n. The probability of early
stopping when S = γ1 is δ/2. Since this should be small, we chose δ = 0.05 in our illustrations.
Another attractive feature of the choice δ = 0.05 is that the practice of calculating 95%
conﬁdence intervals is familiar to our collaborators and they can easily accept abandoning a
biomarker study if the 95% conﬁdence interval does not contain γ1. That is the early stopping
criterion makes sense to collaborators. Observe that one can also consider δ as a type 1 error
for testing H : S = γ1 based on m observations. The corresponding power is the probability
of early stopping under H : S = γ0 . Larger values of m give rise to higher power. An optimal
choice of m might be based on minimizing the expected sample size, which requires postulating
a prior probability distribution for S.
This paper considered biomarkers with dicohotomous values. However, most biomarkers
are measured on a continuous scale and performance is evaluated with the receiver operating
characteristic(ROC) curve. Methods for estimating the ROC curve following a group sequential
phase 2 study would be worthy of research.
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Table I. Results of simulation studies with n = 40 and early termination option at m = 20. Shown
are mean (sd) of estimated sensitivities in studies that reached completion. One thousand simulations
per true sensitivity, S.
True S
% early
stopping Ŝ(all) Ŝ(stage2) Ŵmed Ŵmean Û
55 73% 0.623 0.547 0.576 0.550 0.553
(0.062) (0.112) (0.095) (0.098) (0.102)
60 59% 0.654 0.606 0.619 0.599 0.604
(0.061) (0.109) (0.091) (0.094) (0.096)
65 41% 0.685 0.647 0.662 0.644 0.650
(0.062) (0.102) (0.086) (0.090) (0.091)
70 22% 0.720 0.698 0.709 0.693 0.699
(0.062) (0.099) (0.081) (0.085) (0.084)
75 8% 0.761 0.756 0.760 0.746 0.751
(0.061) (0.097) (0.073) (0.077) (0.075)
80 3% 0.804 0.799 0.809 0.798 0.8000
(0.060) (0.090) (0.067) (0.070) (0.067)
85 1% 0.850 0.851 0.858 0.848 0.849
(0.057) (0.083) (0.059) (0.061) (0.059)
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Table II. Results of additional simulation studies with larger sample sizes. 1000 studies were simulated
for each scenario.
True S
% early
stopping Ŝ(all) Ŝ(stage2) Ŵmed Ŵmean Û
γ0 = 0.95, γ1 = 0.98, n = 230, m = 115
0.90 98% 0.924 0.889 0.890 0.891 0.888
(0.015) (0.029) (0.029) (0.027) (0.028)
0.95 50% 0.957 0.948 0.950 0.948 0.948
(0.012) (0.022) (0.019) (0.022) (0.020)
0.965 22% 0.968 0.965 0.966 0.965 0.965
(0.011) (0.017) (0.014) (0.016) (0.015)
0.98 3% 0.981 0.981 0.981 0.981 0.980
(0.008) (0.012) (0.009) (0.009) (0.009)
0.99 0% 0.990 0.991 0.990 0.990 0.990
(0.007) (0.009) (0.006) (0.007) (0.007)
γ0 = 0.60, γ1 = 0.70, n = 220, m = 110
0.55 91% 0.595 0.553 0.560 0.553 0.555
(0.021) (0.036) (0.033) (0.037) (0.037)
0.60 61% 0.621 0.597 0.600 0.594 0.597
(0.028) (0.050) (0.042) (0.043) (0.044)
0.65 21% 0.659 0.652 0.652 0.649 0.651
(0.028) (0.045) (0.036) (0.038) (0.036)
0.70 2% 0.700 0.699 0.700 0.698 0.698
(0.030) (0.044) (0.032) (0.033) (0.032)
0.75 0% 0.750 0.751 0.751 0.750 0.750
(0.030) (0.040) (0.030) (0.030) (0.030)
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Table III. Results of additional simulation studies with various choices for m/n, the fraction of total
sample size that enters into the first stage evaluation. Data were simulated using the same context as
Table 1, γ0 = 0.60, γ1 = 0.80, n = 40. 1000 simulated studies per scenario.
True S m
% early
stopping Ŝ(all) Ŝ(stage2) Û
0.55 13 59% 0.592 0.549 0.550
(0.065) (0.090) (0.085)
0.60 13 41% 0.628 0.597 0.597
(0.071) (0.098) (0.090)
0.65 13 26% 0.668 0.646 0.647
(0.067) (0.091) (0.082)
0.70 13 19% 0.709 0.693 0.695
(0.069) (0.090) (0.081)
0.75 13 7% 0.756 .747 0.749
(0.066) (0.084) 0.073)
0.80 13 2% 0.804 0.800 0.801
(0.061) (0.078) (0.065)
0.85 13 0% 0.852 0.852 0.851
(0.057) (0.068) (0.059)
0.55 27 84% 0.653 .563 0.560
(0.049) (0.138) (0.112)
0.60 27 68% 0.670 0.588 0.593
(0.056) (0.136) (0.119)
0.65 27 50% 0.698 0.641 0.651
(0.054) (0.130) (0.101)
0.70 27 28% 0.728 0.696 0.700
(0.057) (0.127) (0.091)
0.75 27 14% 0.761 0.748 0.748
(0.060) (0.120) (0.081)
0.80 27 3% 0.803 0.793 0.798
(0.059) (0.112) (0.068)
0.85 27 1% 0.852 0.852 0.851
(0.056) (0.099) (0.058)
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Table IV. Performance of the traditional unconditional UMVUE in studies that complete evaluation
of all n subjects. The scenarios and simulations are the same as in Tables 1 and 2.
γ0 =0.60 γ1 =0.80 n =40 m =20
True S 0.550 0.600 0.650 0.700 0.750 0.800 0.850
mean (U˜) 0.692 0.705 0.720 0.741 0.771 0.808 0.851
sd (U˜) 0.023 0.029 0.035 0.043 0.050 0.054 0.055
γ0 =0.95 γ1 =0.98 n =230 m =115
True S 0.900 0.950 0.965 0.980 0.990
mean (U˜) 0.960 0.966 0.972 0.981 0.990
sd (U˜) 0.002 0.005 0.007 0.008 0.007
γ0 =0.60 γ1 =0.70 n =220 m =110
True S 0.550 0.600 0.650 0.700 0.750
mean (U˜) 0.635 0.646 0.667 0.701 0.750
sd (U˜) 0.005 0.013 0.021 0.028 0.029
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Table V. Estimated mean and sd of Û and coverage of 95% confidence intervals (CI) based on the
2.5th and 97.5th percentiles of the nonparametric and parametric bootstrap distributions of Û . Shown
are results for completed studies in 500 simulations with γ0 = 0.60 and γ1 = 0.80 or γ1 = 0.70. The
number of bootstrap samples per simulated study was chosen to be min(nb, 5000) where nb yielded
500 resampled datasets that satisfied C=1
Parametric Bootstrap Nonparametric Bootstrap
True S number of
completed
studies
mean (Û) sd (Û) mean (ŝd) CI coverage (%) mean (ŝd) CI coverage (%)
γ0 = 0.60 γ1 = 0.80 n = 40 m = 20
0.55 131 0.562 0.092 0.097 92.4 0.123 98.5
0.60 207 0.595 0.111 0.094 92.7 0.116 95.7
0.65 285 0.649 0.092 0.089 93.7 0.107 97.9
0.70 394 0.697 0.083 0.083 95.4 0.097 96.2
0.75 453 0.749 0.077 0.075 93.6 0.085 94.7
0.80 479 0.801 0.068 0.066 95.0 0.072 96.0
0.82 491 0.818 0.065 0.063 93.1 0.067 93.5
0.85 497 0.850 0.059 0.057 93.8 0.059 94.8
γ0 = 0.60 γ1 = 0.70 n = 220 m = 110
0.55 48 0.542 0.048 0.044 89.4 0.053 97.9
0.60 204 0.602 0.041 0.041 94.6 0.049 97.5
0.65 378 0.649 0.038 0.037 93.7 0.042 97.6
0.70 486 0.702 0.032 0.032 95.5 0.034 95.7
0.72 499 0.721 0.028 0.031 96.6 0.032 96.6
0.75 499 0.751 0.030 0.029 94.2 0.030 95.0
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Table VI. Power based on Ŝ(all) in a fixed sample size study of n subjects and power based on Û
in studies that allow early termination. Early stopping uses 1 − δ confidence interval at the interim
analysis. Power for Û is the proportion of studies that reach complete enrollment and 95% confidence
interval does not include γ0. Scenarios of Tables 1 and 2 (lower panel) are employed, m = n/2,
γ0 = 0.60 and δ = 0.05. 500 simulated studies. Values of Û calculated with K = 500.
S n
Early
Stopping
(%) P-BS(Û ) NP-BS(Û) Logit(Ŝ(all))
0.80 40 4.2% 0.722 0.638 0.710
0.82 40 1.8% 0.804 0.724 0.808
0.85 40 0.6% 0.918 0.870 0.920
0.70 220 2.8% 0.802 0.708 0.872
0.72 220 0.2% 0.942 0.904 0.974
0.75 220 0.2% 0.992 0.982 1.000
NP-BS(Û) nonparametric bootstrap; P-BS(Û) parametric bootstrap; Logit(Ŝ(all)) normal
approximation to the distribution of logit(Ŝ(all)).
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Table VII. Eight simulated studies with n = 40, m = 20, γ0 = 0.6, γ1 = 0.8. 95% confidence intervals
are calculated based on Û with the parametric (pCI) or nonparametric (npCI) method.
Study Ŝ(stage1) CI(stage1) Ŝ(stage2) Ŝ(all) U˜ Ŵmed Ŵmean Û npCI pCI
1 0.25 (0.11,0.47) – – – – – – – –
2 0.90 (0.70,0.97) 0.85 0.88 0.88 0.88 0.88 0.87 (0.77,0.98) (0.78,0.98)
3 0.60 (0.39,0.78) – – – – – – – –
4 0.70 (0.48,0.86) 0.55 0.63 0.69 0.58 0.57 0.56 (0.28,0.77) (0.34,0.75)
5 0.75 (0.53,0.89) 0.40 0.58 0.67 0.50 0.46 0.47 (0.15,0.72) (0.25,0.68)
6 0.65 (0.43,0.82) 0.85 0.75 0.76 0.75 0.74 0.74 (0.56,0.88) (0.56,0.88)
7 1.00 (0.84,1.00) 0.70 0.85 0.85 0.86 0.85 0.85 (0.71,0.95) (0.72,0.95)
8 0.50 (0.30,0.70) – – – – – – – –
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Table VIII. Simulated studies using a two-stage design with (nD = 78, mD = 39, γ0 = 0.6, γ1 = 0.8)
and (nD¯ = 572, mD¯ = 286, η0 = 0.95, η1 = 0.98). Coverage and power shown for the conditional
UMVUE estimators of S and F with parametric bootstrapped confidence intervals. Nominal coverage
probability=95%
S F
% Early
Termination
Conditional†
Joint Coverage
Conditional†
Power
Unconditional
Power
Fixed Sample∗
Power
0.6 0.95 95% 92% 0.00 0.00 0.00
0.6 0.98 75% 90% 0.02 0.01 0.02
0.8 0.95 77% 96% 0.01 0.00 0.00
0.8 0.98 2% 94% 0.83 0.81 0.90
0.7 0.97 38% 94% 0.09 0.06 0.13
† restricted to studies that complete both stages; ∗ no option for early termination.
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